Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candida antigen extract patch
- Development stage
- Phase 2
- Lead developer
- Veradermics
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Administration
- Transdermal
01
Overview
A dissolvable microarray-based transdermal patch formulation containing an extract of *Candida albicans* antigens. The product is designed for the treatment of common warts (verruca vulgaris) and acts via immunomodulatory activity. It is being developed as a novel, injection-free approach to wart therapy and is currently in Phase 2 clinical trials for this indication. The developer is Veradermics.
- Other names
- candida antigen extract patchCandida antigen extract patch VDMN-21
02
Targets
γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on candida antigen extract patch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candida antigen extract patch.